Retatrutide and trizepatide are a recent class of medications that bind to both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These combined receptor agonists display significant therapeutic benefits in the management of type 2 diabetes. Retatrutide, a once-weekly subcutaneous injection, stimu